486 related articles for article (PubMed ID: 15476273)
21. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Hultdin M; Sundström G; Wahlin A; Lundström B; Samuelsson J; Birgegård G; Engström-Laurent A
Med Oncol; 2007; 24(1):63-70. PubMed ID: 17673813
[TBL] [Abstract][Full Text] [Related]
22. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
[TBL] [Abstract][Full Text] [Related]
23. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
24. TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.
Palmblad J; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Mauritzson N; Westin J; Samuelsson J; Birgegård G
Int J Med Sci; 2008 Apr; 5(2):87-91. PubMed ID: 18414650
[TBL] [Abstract][Full Text] [Related]
25. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
Schwarz J; Ovesná P; Černá O; Kissová J; Maaloufová Soukupová J; Brychtová Y; Doubek M; Červinek L; Cmunt E; Dulíček P; Campr V; Křen L; Penka M;
Eur J Haematol; 2016 Jan; 96(1):98-106. PubMed ID: 25807961
[TBL] [Abstract][Full Text] [Related]
26. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
27. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.
Spencer CM; Brogden RN
Drugs; 1994 May; 47(5):809-22. PubMed ID: 7520859
[TBL] [Abstract][Full Text] [Related]
28. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.
Petitt RM; Silverstein MN; Petrone ME
Semin Hematol; 1997 Jan; 34(1):51-4. PubMed ID: 9025162
[No Abstract] [Full Text] [Related]
29. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
[TBL] [Abstract][Full Text] [Related]
30. Treatment of children with anagrelide for thrombocythemia.
Lackner H; Urban C; Beham-Schmid C; Benesch M; Kerbl R; Schwinger W
J Pediatr Hematol Oncol; 1998; 20(5):469-73. PubMed ID: 9787322
[TBL] [Abstract][Full Text] [Related]
31. Role of anagrelide in the treatment of thrombocytosis.
Brooks WG; Stanley DD; Goode JV
Ann Pharmacother; 1999 Oct; 33(10):1116-8, 1121. PubMed ID: 10534225
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
33. Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
Antelo ML; de Las Heras N; Gonzalez Porras JR; Kerguelen A; Raya JM
Expert Rev Hematol; 2015 Dec; 8(6):819-35. PubMed ID: 26368319
[TBL] [Abstract][Full Text] [Related]
34. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
35. [Anagrelide for treatment of patients with essential thrombocythaemia].
Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
[TBL] [Abstract][Full Text] [Related]
36. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Trapp OM; Beykirch MK; Petrides PE
Blood Cells Mol Dis; 1998 Mar; 24(1):9-13. PubMed ID: 9516377
[TBL] [Abstract][Full Text] [Related]
37. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Voglová J; Maisnar V; Beránek M; Chrobák L
Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
[TBL] [Abstract][Full Text] [Related]
38. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
Michiels JJ
Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
[TBL] [Abstract][Full Text] [Related]
39. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.
Mills AK; Taylor KM; Wright SJ; Bunce I; Eliadis P; Brigden MC; Seeley G; Bashford J; Olsen T; Rentoul A; Kelly C
Aust N Z J Med; 1999 Feb; 29(1):29-35. PubMed ID: 10200810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]